Immuno-oncology technology · 2026
Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Inthanachai T, Sittplangkoon C, Tashiro H, Yagyu S, Palaga T, Tawinwung S, Suppipat K
Аннотация
BACKGROUND: Acute myeloid leukemia (AML) is a high-risk malignancy, particularly in patients with primary induction failure or relapsed/refractory disease. CD117 (c-Kit), expressed on both leukemic blasts and normal hematopoietic stem and progenitor cells (HSPCs), represents a potential therapeutic target but poses challenges due to the risk of severe myelotoxicity.
MATERIALS AND METHODS: Retrospective flow cytometry analyses of samples from 27 AML patients and AML cell lines were carried out to assess CD117 expression. Second-generation CD117-specific chimeric antigen receptor (CAR) T cells were generated by either retroviral transduction or in vitro-transcribed (IVT) messenger RNA (mRNA) electroporation. The mRNA-based CD117 CAR T cells were evaluated for viability, immunophenotype, cytotoxic activity, and toxicity toward primary HSPCs using clonogenic assays, and compared with retroviral-based counterparts.
RESULTS: CD117 was expressed in AML patient samples and cell lines at varying levels. CD117 CAR T cells demonstrated potent and specific cytotoxicity against AML cells. The mRNA-based CAR T cells exhibited high transfection efficiency, good viability, and an immunophenotype similar to non-transduced T cells, and were functionally competent as early as 2 h post-electroporation. In long-term co-culture with a high tumor burden, repeated dosing of mRNA CAR T cells effectively eliminated CD117+ cells, comparable to viral vector-based CAR T cells. Notably, residual mRNA CAR T cells following AML clearance showed no detectable CAR expression and preserved HSPC colony-forming capacity.
CONCLUSIONS: Our in vitro studies suggest the potential use of mRNA CD117 CAR T cells as a non-genotoxic preconditioning strategy for patients with high-risk or refractory AML.
MATERIALS AND METHODS: Retrospective flow cytometry analyses of samples from 27 AML patients and AML cell lines were carried out to assess CD117 expression. Second-generation CD117-specific chimeric antigen receptor (CAR) T cells were generated by either retroviral transduction or in vitro-transcribed (IVT) messenger RNA (mRNA) electroporation. The mRNA-based CD117 CAR T cells were evaluated for viability, immunophenotype, cytotoxic activity, and toxicity toward primary HSPCs using clonogenic assays, and compared with retroviral-based counterparts.
RESULTS: CD117 was expressed in AML patient samples and cell lines at varying levels. CD117 CAR T cells demonstrated potent and specific cytotoxicity against AML cells. The mRNA-based CAR T cells exhibited high transfection efficiency, good viability, and an immunophenotype similar to non-transduced T cells, and were functionally competent as early as 2 h post-electroporation. In long-term co-culture with a high tumor burden, repeated dosing of mRNA CAR T cells effectively eliminated CD117+ cells, comparable to viral vector-based CAR T cells. Notably, residual mRNA CAR T cells following AML clearance showed no detectable CAR expression and preserved HSPC colony-forming capacity.
CONCLUSIONS: Our in vitro studies suggest the potential use of mRNA CD117 CAR T cells as a non-genotoxic preconditioning strategy for patients with high-risk or refractory AML.